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Identity 
Other names: A20; MGC104522; MGC138687; 
MGC138688; OTUD7C; TNFA1P2 
HGNC (Hugo): TNFAIP3 
Location: 6q23.3 
Local order: TNFAIP3 is located on chromosome 6 on 
the long arm (forward strand), and lies between the 
PERP (PERP, TP53 apoptosis effector) and OLIG3 
(oligodendrocyte transcription factor 3) genes. 
Note 
TNFAIP3 is a gene whose expression is induced by 
TNF (tumor necrosis factor). TNFAIP3 encodes a 
cytoplasmatic zinc finger protein that inhibits NFKB 
(nuclear factor of kappa light polypeptide gene  
enhancer in B-cells) activation and TNF-mediated 
apoptosis. Studies in knockout mice show that 
TNFAIP3 is important for limiting inflammation by 
terminating TNF-induced NFKB responses. 
DNA/RNA 
Description 
TNFAIP3 is a functioning gene of 15869 bp 
comprising 9 exons and 8 introns. Exon 1, the 5' part of 
exon 2 and the 3' part of exon 9 are non coding. 
Transcription 
Length of the transcript is 4446 bp. 
Coding sequence: CDS 67-2439.  
mRNA is expressed at high levels in lymph nodes, 
respiratory tract, larynx, trachea and kidney. 
 
A. Chromosomal location of TNFAIP3 gene.  
B. Mapping of TNFAIP3 gene and local order on genomic context of the chromosome 6. 
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Exon-intron structure of the TNFAIP3 gene. Blue boxes correspond to protein coding regions, while white boxes correspond to non 
coding regions. 
 
Representation of the TNFAIP3 protein with localization of recognized domains. The ovarian tumor domain (OTU) is shown in green, 




Protein length of the unprocessed precursor: 790 amino 
acids. 
Molecular weight of the unprocessed precursor: 89614 
Da. 
TNFAIP3 is a zinc finger protein containing seven 
A20-type finger motifs (E3 ubiquitin ligase domain)  
its C-terminal region and a deubiquitinating enzyme 
domain, termed ovarian tumor (OTU) domain, in its N-
terminal region. TNFAIP3 belongs to the peptidase 
C64 family. It is a homodimer that interacts with: 
-TNIP1 (TNFAIP3 interacting protein 1, also known as 
Naf1 or ABIN-1), 
-TAX1BP1 (Tax1 binding protein 1, also known as 
TXBP151 or T6BP), 
-ITCH (itchy E3 ubiquitin protein ligase homolog 
(mouse)), 
-RNF11 (ring finger protein 11), 
-TRAF1, TRAF2, TRAF6 (TNF receptor-associated 
factor 1, 2 and 6). 
Expression 
Expression of TNFAIP3 is induced by TNF and is 
repressed by PML (promyelocytic leukemia) protein. 
Localisation 
Cytoplasm and nucleus. 
Function 
TNFAIP3 inhibits activation of NFKB and AP-1 
transcription factors, and TNF- and IL-1beta 
(interleukin-1beta)-induced apoptosis.  
TNFAIP3 is critical for limiting inflammatory 
processes by terminating TNF-induced NFKB 
responses, and contributes to the in vivo effects of 
TNF. 
TNFAIP3 also restricts NFKB signaling in response to 
stimulation of TLR (toll-like receptor) and NOD 
(nuclear-binding and oligomerization domain) 
pathways. 
TNFAIP3 possesses dual ubiquitin-editing functions. I  
particular, the N-terminal domain of TNFAIP3 is a 
deubiquitinating enzyme (DUB) for Lys63-linked 
polyubiquitinated signaling mediators such as 
TRAF2/6 and RIP1 (receptor interacting protein 1). 
Instead, the C-terminal domain of TNFAIP3 is a 
ubiquitin ligase (E3) for Lys48-linked degradative 
polyubiquitination of the same substrates. TNFAIP3 
has a specificity for particular polyubiquitinated 
substrates to regulate NFKB activation in the TNF, IL-
1beta and TLR pathways. 
TNFAIP3 has a role in the function of the lymphoid 
system because it inhibits NFKB signaling and may 
play an important role in lymphomagenesis. TNFAIP3 
also negatively regulates the activity of CARD10 
(caspase recruitment domain family, member 10) and 
BCL10 (B-cell CLL/lymphoma 10) in lymphoid and 
non-lymphoid cells. 
A TNFAIP3-mediated inhibition of TNF-induced 
apoptosis is associated with the inhibition of caspase-8. 
TNFAIP3 acts forming a multiprotein complex with 
other proteins, in particular ABIN-1, TAX1BP1, ITCH, 
RNF11, TRAF1, TRAF2, TRAF6, to regulate NFKB 
signaling cascade and TNF-induced cell death. 
TNFAIP3 negatively regulates the maturation, 
inflammatory cytokine production and 
immunostimulatory potency of dendritic cells. 
Homology 
Interspecies: ortholog to murine TNFAIP3 and 
homolog to Caenorhabditis elegans F21C3.2. 
Mutations 
Somatic 
Deletions and bi-allelic somatic mutations involving 
TNFAIP3 gene have been identified in different 
subtypes of B-cell lymphomas. Most of the TNFAIP3 
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mutations are nonsense or frameshift that prevent 
production of full-length TNFAIP3 protein. 
Implicated in 
Marginal Zone B-cell Lymphoma 
(MZBCL) 
Disease 
The incidence of MZBCL in the Western world is 
approximately 10% of all non-Hodgkin's lymphomas 
(NHLs). MZBCL includes three distinct 
clinicopathological forms:  
1- Extranodal MZBCL of mucosa-associated lymphoid 
tissue (MALT) type, 
2- Splenic MZBCL, 
3- Nodal MZBCL. 
The TNFAIP3 gene, that is a common genetic target in 
B-cell lymphomas, is frequently inactivated by somatic 
mutations and/or deletions in MALT lymphoma. 
Homozygous deletions of the chromosomal band 6q23, 
involving the TNFAIP3 gene, were identified in ocular 
adnexal MZBCLs. Inactivating mutations encoding 
truncated TNFAIP3 protein were also identified in 
extranodal, nodal and splenic MZBCLs. 
Prognosis 
The patients usually have prolonged survival, but some 
cases may feature an aggressive disease. In ocular 
adnexal MZBCLs, TNFAIP3 deletion appears to be 
associated with adverse clinical parameters and with
concurrent involvement of different adnexal tissues or 
extraocular sites at diagnosis. TNFAIP3 deletion is also 
associated with a higher proportion of relapse and with
a shorter relapse-free survival. 
Oncogenesis 
TNFAIP3 inactivation by somatic mutation and/or 
deletion represents a genetic aberration across all 
MZBCL subtypes, which may contribute to 
lymphomagenesis by inducing constitutive NFKB 
activation. This suggests that TNFAIP3 may act as a 
tumor suppressor gene in MZBCLs. 
Classical Hodgkin's Lymphoma (cHL) 
Disease 
cHL is a disease that involves a clonal expansion of 
neoplastic B lymphocytes. A constitutive NFKB 
activity has been detected in cHL and somatic 
mutations have been identified in the TNFAIP3 gene. 
Both TNFAIP3 alleles are inactivated, with frequent 
chromosomal deletion of TNFAIP3. Reconstitution of 
wild-type protein in TNFAIP3-deficient cHL cell lines 
results in a downregulation of NFKB activity and in 
suppression of cell growth with induction of apoptosis. 
In fact TNFAIP3-deficient cells generate tumours in 
immunodeficient mice, whereas the re-expression of 
TNFAIP3 suppresses the tumorigenicity. 
Oncogenesis 
TNFAIP3 has been identified in cHL, as in other B-cell 
lymphomas, as a tumor suppressor gene. Loss of 
TNFAIP3 function, inducing a constitutive activity of
NFKB, is probably involved in the pathogenesis of 
cHL. 
Diffuse Large B-cell Lymphoma 
(DLBCL) 
Disease 
DLBCL is the most common type of lymphoma in 
adulthood and is a heterogeneous disease, with patients 
exhibiting a wide range of clinical variables, outcomes 
and responses to therapy. In fact DLBCL includes 
different biologically and clinically distinct subtypes: 
- Germinal centre B-cell-like (GCB) DLBCL, 
- Activated B-cell-like (ABC) DLBCL.  
ABC-DLBCL, that is the most aggressive subtype, is 
associated with constitutive activation of NFKB. ABC-
DLBCL and a smaller fraction of GCB-DLBCL carry 
somatic mutations in TNFAIP3 gene. In fact, 
approximately 30% of patients display biallelic 
inactivation of TNFAIP3 by mutations and/or 
deletions. Reconstitution of TNFAIP3 induces 
apoptosis and cell growth arrest, indicating a tumor 
suppressor role of the gene. 
Oncogenesis 
NFKB activation in DLBCL is caused by genetic 
lesions affecting multiple genes, including TNFAIP3. 
Alterations of these genes may promote 
lymphomagenesis by leading to abnormally prolonged 
NFKB responses. 
Primary Mediastinal B-cell Lymphoma 
(PMBL) 
Disease 
PMBL is a subtype of DLBCL defined by a 
combination of clinical and pathologic features. PMBL 
typically presents in young female patients, that hve 
bulky mediastinal masses with frequent invasion of 
adjacent structures. PMBL is a lymphoma with 
constitutive NFKB activity and significantly high 
frequency of TNFAIP3 mutations. 
Oncogenesis 
TNFAIP3 has been identified as a tumor suppressor 
gene in PMBL by showing frequent somatic and clonal 
biallelic inactivation of the gene. Loss of TNFAIP3 
function contributes to the constitutive activity of the 
transcription factor NFKB and the survival and/or 
proliferation of the cells. 
Breast cancer 
Disease 
Breast cancer is the most common cancer among 
women in developed countries. The etiology is 
multifactorial and the majority of these tumors express 
estrogen receptor (ER). Tamoxifen has been shown to 
be an effective adjiuvant therapy for ER+ tumors, but 
only 60% of ER+ tumors respond to this therapy. 
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TNFAIP3 is overexpressed in breast cancer cells and 
confers resistance to tamoxifen-induced cytotoxicity. 
Prognosis 
TNFAPI3 represents a potential prognostic marker of 
breast cancer, because an increased expression of 
TNFAIP3 is associated with an aggressive phenotype 
of the disease. 
Oncogenesis 
TNFAIP3 is probably a key protein involved in 
tamoxifen resistance in breast cancer because it is
overexpressed in tamoxifen-resistant cell lines. It is a 
possible target for developing new strategies to prevent 
drug resistance in breast cancer. 
Nasopharyngeal carcinoma (NPC) 
Disease 
TNFAIP3 expression is correlated with the 
differentiation stages of NPC. In particular, TNFAIP3 
expression contributes to the development of 
undifferentiated NPC as well as poorly differentiated 
head and neck squamous cell carcinomas (SCCs). 
Oncogenesis 
TNFAIP3 may have a role in the pathogenesis and 
aggressiveness of these tumors, probably because 
TNFAIP3 is implicated in survival pathways. 
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